Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS

Development and Commercialisation of a Self-Guided Fluidised Bed Granulation Solution

Ziel

The proposed Innovation Project aims to develop and commercialise the world’s first Self-Guided Fluidised Bed Granulation Solution targeted at the pharmaceutical, food, nutritional and cosmetics industries. The SMART-GRAN solution will incorporate a suite of Process Analytical Technology (PAT) analysers for the in-process monitoring and closed loop control of the Critical Process Parameters (physical, chemical and moisture properties of the granulate) coupled with soft-sensoring, for obtaining consistent product quality and safety. The ability of the system to confirm cleaning process success between batches will reduce equipment downtime, increase product throughput and lead to increased productivity. Through a cloud-based data management platform, the SMART-GRAN solution will enable historical data to be available for Quality-by-Design process optimisation for gaining resource efficiencies for improved competitiveness. This will enable intelligence-based manufacturing (IbM) concepts which focus on harnessing the complementary power of data, modelling, engineering and IT infrastructure by transforming data into knowledge and ultimately intelligence, to equip industry to move to proactive manufacturing strategies that deliver predictable manufacturing performance. The commercialization of the system will help IPL to secure a position as a global PAT-based solutions provider to the pharmaceutical sector, generating > € 34 M in additional turnover for the company by 2022, and leading directly to the creation of ~58 new high-end jobs through the supply of the system. Roll out to other sectors will treble this potential. Moreover, the competitive impacts upstream and downstream will lead to the creation of up to ~1000 new jobs in Europe.

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2014

Koordinator

INNOPHARMA LABS LIMITED
Netto-EU-Beitrag
€ 1 724 012,50
Adresse
ASHFIELD CRONE LOWER
Y14 REDCROSS
Irland

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
Ireland Eastern and Midland Dublin
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 2 462 875,00